Primary Sclerosing Cholangitis Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 22, 2019--
The “Primary Sclerosing Cholangitis - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Primary Sclerosing Cholangitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 2, 11 and 1 respectively.
Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dgoqou
View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005691/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Liver and Kidney Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/22/2019 12:55 PM/DISC: 05/22/2019 12:55 PM